MIRA ONCOLOGY Trademark

Trademark Overview


On Monday, April 15, 2024, a trademark application was filed for MIRA ONCOLOGY with the United States Patent and Trademark Office. The USPTO has given the MIRA ONCOLOGY trademark a serial number of 98501181. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Monday, November 4, 2024. The MIRA ONCOLOGY trademark is filed in the Pharmaceutical Products category with the following description:

Antibodies for use in the treatment of cancer
mira oncology

General Information


Serial Number98501181
Word MarkMIRA ONCOLOGY
Filing DateMonday, April 15, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateMonday, November 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesAntibodies for use in the treatment of cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressBOYNTON BEACH, FL 33437

Trademark Events


Event DateEvent Description
Monday, April 15, 2024NEW APPLICATION ENTERED
Monday, April 15, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 29, 2024ASSIGNED TO EXAMINER
Monday, November 4, 2024NON-FINAL ACTION WRITTEN
Monday, November 4, 2024NON-FINAL ACTION E-MAILED
Monday, November 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED